EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 585 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’... December 12, 2021 Zanubrutinib’s Approval Improves Targeted Treatment for CLL January 27, 2023 Army Veteran Gets Life-Saving Heart Transplant: ‘It’s A True Miracle’ November 29, 2021 Speaking a thousand words – how a cancer image collection is... September 8, 2021 Load more HOT NEWS New Technology System Allows Patients To Get A Mammogram And Biopsy... Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined
